A higher immune score (Wilcoxon test, p-value = 3.9e-06; Figure 2D), CD8 T cell score (Wilcoxon test, p-value = 8.5e-06; Figure 2F), HRD (Wilcoxon test, p-value = 6.02e-06; Figure 2G), IFN-γ expression signature (Wilcoxon test, p-value = 0.00098; Figure 2H), CYT activity (Wilcoxon test, p-value = 0.0035; Figure 2I), TILs score (Wilcoxon test, p-value = 2.7e-07; Figure 2K), TIS score (Wilcoxon test, p-value = 0.00049; Figure 2L) and TMB (Wilcoxon test, p-value = 0.00016; Figure 2M) were observed in the low-risk group of NSCLC patients. This evidence concerns the gene IFNG and non-small cell lung carcinoma.